Poor results for everolimus in patients with liver cancer

The Lancet Oncology, Volume 15, Issue 9, Page e368, August 2014

doi:10.1016/S1470-2045(14)70318-3Cite or Link Using DOI

Published Online: 11 July 2014

Copyright © 2014 Elsevier Ltd All rights reserved.

Poor results for everolimus in patients with liver cancer

Talha Khan Burki

Everolimus is ineffective in treating patients with advanced hepatocellular carcinoma who are either refractory to or intolerant of sorafenib, according to a phase 3 study . The randomised trial of 546 patients (362 assigned to everolimus and 184 to placebo) showed that the mTOR inhibitor offered no survival benefit. 303 (84%) patients died in the everolimus group compared with 151 (82%) in the placebo group (hazard ratio [HR ] 1·05, 95% CI 0·86—1·27; p=0·68).

Advertisements

Author: CA Care

In obedience to God's will and counting on His mercies and blessings, and driven by the desire to care for one another, we seek to provide help, direction and relief to those who suffer from cancer.

1 thought on “Poor results for everolimus in patients with liver cancer”

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s